Management of small cell lung cancer: Current state of the art

Chest

Volumn 116, Issue 6 SUPPL., 1999, Pages 525S-530S

  Johnson, David H ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; VINCRISTINE;

ARTICLE; BRAIN RADIATION; CANCER RADIOTHERAPY; DOSE CALCULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REMISSION;

EID: 0033400222     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Ihde DC, Pass III, Glatstein EJ. Small cell lung cancer. In: DeVita VT Jr. Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia, PA: JB Lippincott, 1993; 723-758
2. Blanke CD, Johnson DH. Treatment of small cell lung cancer. Semin Thorac Cardiovasc Surg 1997; 9:101-110
3. Ettinger DS, Finkelstein DM, Sarma RP, et al. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995; 13:1430-1435
4. Schiller JH, Kim KM, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1996; 14:2345-2352
5. Bonomi P, Kim K, Chang A, et al. Phase III trial comparing etoposide (E) cisplatin (C) versus taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non-small cell lung cancer: an Eastern Cooperative Group (ECOC) trial [abstract 1145]. Proc Am Soc Clin Oncol 1996; 15:382
6. Lowenbraun S, Bartolucci A, Smaller RV, et al. The superiority of combination chemotherapy over single agent chemotherapv in small cell lung carcinoma. Cancer 1979; 44:406-413
7. Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment lor advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997; 89:577-580
8. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial: Medical Research Council Lung Cancer Working Party. Lancet 1996; 348:563-566
9. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994; 12:2022-2034
10. Lyman GH, Lyman CG, Sanderson RA, et al. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993; 85:488-493
11. Nichols CR, Fox EP, Roth BJ, et al. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 1994; 12:1245-1250
12. Radford JA, Ryder WD, Dodwell D, et al. Predicting septic-complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer 1992; 29A:81-86
13. Stephens RJ, Girling DJ, Machin D. Treatment-related deaths in small cell lung cancer trials: can patients at risk be identified? Medical Research Council Lung Cancer Working Party. Lung Cancer 1994; 11:259-274
14. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83:855-861
15. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive stage small cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10:282-291
16. Raghavan D, Bishop JF, Stuart-Harris R, et al. Carboplatin-containing regimens for small cell lung cancer: implications for management in the elderly. Semin Oncol 1992; 19(suppl 2):12-16
17. Matsui K, Takada M, Masuda N, et al. Pilot study of carboplatin (CBDCA) calculated by Egorin's formula plus oral etoposide (ETP) for elderly patients with small cell lung cancer (SCLC) [abstract 1179]. Proc Am Soc Clin Oncol 1994; 13:352
18. Evans WK, Radwi A, Tomiak E, et al. Oral etoposide and carboplatin: effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol 1995; 18:149-155
19. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer: a Hellenic Cooperative Oncology Group study. Ann Oncol 1994; 5:601-607
20. Figueredo AT, Hrynink WM, Strantmanis I, et al. Cotrimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 1985; 3:54-64
21. Johnson DH, DeLeo MJ, Hande KR, et al. High-dose induction chemotherapy with cyclophosphamide, etoposide, and cisplatin for extensive-stage small-cell lung cancer. J Clin Oncol 1987; 5:703-709
22. Pujol J-L, Douillard J-Y, Rivière A, et al. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant granulocyte-macrophage colony-stimulating factor in extensive-stage small cell lung cancer: a multicenter randomized phase III study. J Clin Oncol 1997; 15:2082-2089
23. Johnson DH, Wolff SN, Hainsworth JD, et al. Extensive-stage small cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide. J Clin Oncol 1985; 3:170-175
24. Ihde DC, Mulshine JL, Kramer BS, et al. Randomized trial of high vs. standard dose etoposide (VP16) and cisplatin in extensive stage small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1991; 10:240
25. Schabel FM, Griswold DP, Corbett TH, et al. Testing therapeutic hypotheses in mice and man: observations on the therapeutic activity against advanced solid tumors of mice treated with anticancer drugs that have demonstrated or potential clinical utility for treatment of advanced solid tumors in man. In: DeVita VT, Busch H, eds. Methods in cancer research. Cancer drug development, part B. Vol. XVII. New York, NY: Academic Press, 1979; 4-52
26. Bunn PA Jr, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Croup. J Clin Oncol 1995; 13:1632-1641
27. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977; 61:1307-1317
28. Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987; 5:1864-1873
29. Elias AD, Ayash L, Frei E III, et al. Intensive combined modality therapy for limited-stage small cell lung cancer. J Natl Cancer Inst 1993; 85:559-566
30. Johnson DH, Bass D, Einhorn LH, et al. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J Clin Oncol 1993; 11: 1223-1229
31. Murray N, Shah A, Osoba D, et al. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 1991; 9:1632-1638
32. Murray N, Livingston R, Shepherd F, et al. A randomized study of CODE plus thoracic irradiation versus alternating CAV/EP for extensive stage small cell lung cancer (ESCLC) [abstract 1638]. Proc Am Soc Clin Oncol 1997; 16:456a
33. Sculier JP, Paesmans M, Bureau G, et al. Multiple drug weekly chemotherapy versus combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 1993; 11:1858-1865
34. Souhami RL, Rudd R, Ruiz de Elvira M-C, et al. Randomized trial comparing weekly versus 3-week chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol 1994; 12:1806-1813
35. Furuse K, Kubota K, Nishiwaki Y, et al. Phase III study of dose intensive weekly chemotherapy with recombinant human granulocyte-colony stimulating factor (G-CSF) versus standard chemotherapy in extensive stage small cell lung cancer (SCLC) [abstract 1117]. Proc Am Soc Clin Oncol 1996; 15:375
36. Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemutherapy. Cancer Treat Rep 1982; 66:439-449
37. Evans WK, Feld R, Murray N, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: a multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med 1987; 107:451-458
38. Clarke SJ, Bell DR, Woods RL, et al. Maintenance chemotherapy for small cell carcinoma of the lung: long term follow-up [abstract]. Proc Am Soc Clin Oncol 1989; 8:248
39. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer: Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer 1989; 59:584-590
40. Spiro SG, Souhami RL, Geddes DM, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1989; 59:578-583
41. Giaccone G, Dalesio O, McVie G, et al. Maintenance chemotherapy in small cell lung cancer: long-term results of a randomized trial: European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1993; 11:1230-1240
42. Sculier JP, Paesmans M, Bureau G, et al. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small cell lung cancer: European Lung Cancer Working Party. J Clin Oncol 1996; 14:2337-2344
43. Blechen NM, Girling DJ, Machin D, et al. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC): II. Quality of life; Medical Research Council Lung Cancer Working Part). Br J Cancer 1993; 68:1157-1166
44. Johnson DH, Kim K, Sause W, et al. Cisplatin (P) and etoposide (E) + thoracic radiotherapy (TRT) administered once or twice daily (BID) in limited stage (LS) small cell lung cancer (SCLC): final report of intergroup trial 0096 [abstract 1113]. Proc Am Soc Clin Oncol 1996; 15:374
45. Andersen M, Kristjansen PE, Hansen HH. Second-line chemotherapy in small cell lung cancer. Cancer Treat Rev 1990; 17:427-436
46. Batist G, Ihde DC, Zabell A, et al. Small-cell carcinoma of the lung: reinduction therapy after late relapse. Ann Intern Med 1983; 98:472-474
47. Giaccone G, Ferrati P, Donadio M, et al. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987; 23:1697-1699
48. Vincent M, Evans B, Smith I. First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol 1988; 21:45-48
49. Johnson DH, Greco FA, Strupp J, et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a phase II trial. J Clin Oncol 1990; 8:1613-1617
50. Giaccone G, Donadio M, Bonardi G, et al. Teniposide in the treatment of small cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 1988; 6:1264-1270
51. Ardizzoni A, Hansen H, Dombernowsky P, et al. Phase II study of topotecan in pretreated small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1994; 13:336
52. Wanders J, Ardizzoni A, Hansen HH, et al. Phase II study of topotecan in refractory and sensitive small cell lung cancer [abstract]. Proc Am Assoc Cancer Res 1995; 36:237
53. Takada M, Fukuoka M, Furuse K, et al. Phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with cisplatin (C) and etoposide (E) (or limited-stage (LS) small cell lung cancer (SCLC): preliminary results of the Japan Clinical Oncology Croup (JCOG) [abstract 1103]. Proc Am Soc Clin Oncol 1996; 15:372
54. Gregor A, Drings P, Burghouts J, et al. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. J Clin Oncol 1997; 15:2840-2849
55. Lebeau B, Chastang Cl, Urban T, et al. A randomized clinical trial comparing concurrent and alternated thoracic irradiation in limited small cell lung cancer (SCLC) [abstract 1148]. Proc Am Soc Clin Oncol 1996; 15:383
56. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987; 316:912-918
57. Perry MC, Herndon JE, Eaton WL, et al. Thoracic radiation therapy added to chemotherapy in limited small cell lung cancer: an update of Cancer & Leukemia Group B (CALGB) study 8083 [abstract 1150]. Proc Am Soc Clin Oncol 1996; 15:384
58. Work E, Nielsen OS, Bentzen SM, et al. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer: Aarhus Lung Cancer Group. J Clin Oncol 1997; 15:3030-3037
59. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer: the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993; 11:336-344
60. Jeremic B, Shibamoto Y, Acimovic L, et al. Initial versus delayed accelerated lyperfractionated radiation therapy and concurrent chemotherapy in limited stage small-cell lung cancer: a randomized study. J Clin Oncol 1997; 15:893-900
61. Carney DN, Mitchell JB, Kinsella TJ. In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. Cancer Res 1983; 43:2806-2811
62. Turrisi AT III, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265-271
63. Bunn PA Jr, Kelly K. Prophylactic cranial irradiation for patients with small-cell lung cancer. J Natl Cancer lust 1995; 87:161-162
64. Johnson BE, Becker B, Goff WB II, et al. Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2-to 10-year survivors of small-cell lung cancer. J Clin Oncol 1985; 3:1659-1667
65. Komaki R, Meyers CA, Shin DM, et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys 1995; 33:179-182
66. Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995; 87:183-190